Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 91

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 91
---
inatus may be subject to penalties if it fails to comply with regulatory requirements or experiences unanticipated problems with the Liminatus assets.

•

Liminatus’s business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose it to penalties.

•

Healthcare legislative reform discourse and potential or enacted measures may have a material adverse impact on Liminatus’s business and results of operations and legislative or political discussions surrounding the desire for and implementation of pricing reforms may adversely impact its business.

•

Liminatus is subject to laws and regulations related to privacy, data protection, information security and consumer protection across different markets where it conducts its business. Liminatus’s actual or perceived failure to comply with such obligations could harm its business.

Risks Related to Iris and the Nature of its Business

•

Risks and conditions related to Iris’s liquidity and capital resources raise substantial doubt about Iris’s ability to continue as a going concern.

•

If Iris is unable to complete a business combination or amend the Iris Certificate of Incorporation by stockholder approval by March 31, 2025 (subject to an additional three month extension at the discretion of the Iris Board), Iris will be forced to wind up.

•

There is no guarantee that a stockholder’s decision whether to redeem their shares for a pro rata portion of the Trust Account will put the stockholder in a better future economic position.

<div align='center'>21</div>

TABLE OF CONTENTS

•

Iris’s stockholders may be held liable for claims by third parties to the extent of distributions they received.

•

Risks related to the delisting of Iris’s securities by Nasdaq.

•

Risks related to Iris being deemed to be an investment company under the Investment Company Act.

Risks Related to the Business Combination

•

The Sponsor, Iris’s directors and executive officers, and their affiliates, own interests in Iris that will be worthless if the transactions are not approved, which may have influenced their decisions.

•

Iris may not be able to realize the anticipated benefits from the Business Combination.

•

Each of Iris and Liminatus will incur substantial costs in connection with the Business Combination.

•

Iris’s ability to consummate the Business Combination may be negatively impacted because neither the Iris Board nor any committee of the Iris Board obtained a fairness opinion in determining whether or not to pursue the Business Combination, and as a result, the terms may not be fair from a financial point of view to